Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature

Medicine (Baltimore). 2018 Jul;97(30):e11614. doi: 10.1097/MD.0000000000011614.

Abstract

Background: It is thought that expression of programmed death ligand-1 (PD-L1) in esophageal cancer (EC) might compromise patient survival. However, the association between PD-L1 expression and survival of patients with EC remains controversial.

Methods: A meta-analysis combining eligible published studies was performed to evaluate the effect of PD-L1 expression in tumor cells detected by immunohistochemistry (IHC) on overall survival (OS) and disease-free survival (DFS) in patients with EC, using pooled hazard ratio (HR) with its 95% confidence interval (CI).

Results: The pooled HR for 19 eligible studies (18 publications, n = 3306) suggested that PD-L1 overexpression had an unfavorable impact on OS (HR = 1.42, 95% CI: 1.09-1.86). No significant effect of PD-L1 overexpression on DFS was observed, and the combined HR was 1.08 (95% CI: 0.76-1.53) for 12 eligible studies (11 publications, n = 2260).

Conclusion: PD-L1 expression in tumor cells detected by IHC was associated with worse OS in EC. However, the prognostic value of PD-L1 expression in tumor cells on OS in EC still needs further large prospective trials to be clarified.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Disease-Free Survival
  • Esophageal Neoplasms / metabolism*
  • Esophageal Neoplasms / mortality*
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Prognosis
  • Programmed Cell Death 1 Receptor / metabolism*
  • Proportional Hazards Models

Substances

  • Biomarkers, Tumor
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor